Real-world data (RWD) — and the real-world evidence (RWE) derived from these data — have made a splash in the life sciences industry in recent years, accelerating learning and driving impact for patients.
Sources like claims data and electronic health records (EHRs) capture the patient journey across specialties and sites of care. This helps life sciences manufacturers analyze their product in real-world care settings. These data can provide deep insights on costs, outcomes and health care utilization.
Those insights help shape decisions related to regulatory approvals, payer contracts and more.
When it comes to RWE and data, trust Optum
The breadth and depth of Optum® data and expertise make us a key partner to leading life sciences organizations. We’ve served the life sciences market for 25 years and more than 1,000 publications have employed our RWD in the past 10 years.
In 2023, Optum was recognized as Frost & Sullivan’s Company of the Year for best-in-class RWE information technology solutions. In addition, the IDC MarketScape: Worldwide Life Science R&D RWE, RWD, Platforms, Technologies, and Consulting Services 2023 Vendor Assessment* recognized us as an industry leader.
Recently, we became a member of the Decentralized Trials & Research Alliance (DTRA), an industry group dedicated to accelerating patient-focused, decentralized clinical trials. We focus on these trials through our RWD-powered clinical trial solutions.
Now, we’re taking the next step in championing the use of RWE and data by joining the RWE Alliance, a group of real-world data and analytics organizations committed to advancing the use of RWE in regulatory decision-making.
The RWE Alliance brings together industry groups who recognize the value of RWE in bringing new treatments to patients. The industry coalition is dedicated to advocating for policies that support the use of RWE in stakeholder decision-making. With our commitment to helping clients harness regulatory-grade RWE across the product lifecycle, Optum is proud to join this group and work to further its goals.
Growing viable use cases for RWE across the product lifecycle
Early use cases for RWE among life sciences companies focused on post-approval studies that enhanced value messaging for health care providers and payers, justified label expansions or surveilled long-term safety. Now, RWE is poised to support a wider range of critical activities, starting at pre-launch.
These activities include early-stage research through clinical development, launch planning, value-based contracting, long-term monitoring and ongoing patient activation. RWE can even play a role in strategic road mapping, helping to determine how attractive potential markets can be.